Cypripedin, a phenanthrenequinone from Dendrobium densiflorum, sensitizes non-small cell lung cancer H460 cells to cisplatin-mediated apoptosis

  • Onsurang Wattanathamsan
  • Surassawadee Treesuwan
  • Boonchu Sritularuk
  • Varisa Pongrakhananon
Original Paper

Abstract

The life-threatening potential of lung cancer has increased over the years due to its acquisition of chemotherapeutic resistance, especially to cisplatin, a first-line therapy. In response to this development, researchers have turned their attention to several compounds derived from natural origins, including cypripedin (CYP), a phenanthrenequinone substance extracted from Dendrobium densiflorum. The aim of the present study was to investigate the ability of CYP to induce apoptosis and enhance cisplatin-mediated death of human lung cancer NCI-H460 cells using cell viability and apoptosis assays. The induction of apoptosis by CYP was observed at a concentration of > 50 μM with the appearance of morphological changes, including DNA condensation and chromatin fragmentation. Together with, CYP was able to activate caspase-3 and downregulate the anti-apoptotic proteins Bcl-2 and Bcl-xL. Also, a non-cytotoxic dose of CYP synergistically potentiated the effect of cisplatin in non-small cell lung cancer line H460 cells, which clearly exhibited the apoptotic phenotype. Western blot analysis revealed that the underlying mechanism involved the downregulation of anti-apoptotic Bcl-xL, whereas the levels of other apoptotic regulatory proteins were not altered. This study provides interesting information on the potent effect of CYP as a chemotherapeutic sensitizer that could be further developed to improve the clinical outcomes of lung cancer patients.

Keywords

Apoptosis Cisplatin Cypripedin Lung cancer 

Notes

Acknowledgements

This research was supported by the Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest.

References

  1. 1.
    Miller KD, Siegel RL, Lin CC (2016) Cancer treatment and survivorship statistics. CA Cancer J Clin 66:271–289CrossRefPubMedGoogle Scholar
  2. 2.
    Ettinger DS, Akerley W, Borghaei H (2012) Non-small cell lung cancer. J Natl Compr Canc Netw 10:1236–1271CrossRefPubMedGoogle Scholar
  3. 3.
    Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265–7279CrossRefPubMedGoogle Scholar
  4. 4.
    Florea AM, Büsselberg D (2011) Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3:1351–1371CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Oosterwijk JGV, Herpers B, Meijer D, Briaire-de BIH, Cleton-Jansen AM, Gelderblom H, van de Water B, Bovee JV (2012) Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Ann Oncol 23:1617–1626CrossRefPubMedGoogle Scholar
  6. 6.
    Kumar Biswas S, Huang J, Persaud S, Basu A (2004) Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Mol Cancer Ther 3:327–334PubMedGoogle Scholar
  7. 7.
    Nishioka T, Luo LY, Shen L, Mariyannis A, Dai W, Chen C (2014) Nicotine increases the resistance of lung cancer cells to cisplatin through enhancing Bcl-2 stability. Br J Cancer 110:1785–1792CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Leisching G, Loos B, Botha M, Engelbrecht A-M (2015) Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance. J Transl Med 13:328CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chen HC, Kanai M, Inoue-Yamauchi A, Tu HC, Huang Y, Ren D, Ganesan YT (2015) An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nat Cell Biol 17:1270CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Williams MM, Lee L, Hicks DJ, Joly MM, Elion D, Rahman B, Estrada MV (2017) Key survival factor, Mcl-1, correlates with sensitivity to combined Bcl-2/Bcl-xL blockade. Mol Cancer Res 15:259–268CrossRefPubMedGoogle Scholar
  11. 11.
    Brotin E, Meryet-Figuière M, Simonin K, Duval RE, Villedieu M, Leroy-Dudal J, Poulain L (2010) Bcl-xL and Mcl-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Int J Cancer 126:885–895PubMedGoogle Scholar
  12. 12.
    Chen XM, Dong HL, Hu KX, Sun ZR, Chen J, Guo SX (2010) Diversity and antimicrobial and plant-growth-promoting activities of endophytic fungi in Dendrobium loddigesii Rolfe. J Plant Growth Regul 29:328–337CrossRefGoogle Scholar
  13. 13.
    Simmler C, Antheaume C, Lobstein A (2010) Antioxidant biomarkers from Vanda coerulea stems reduce irradiated HaCaT PGE-2 production as a result of COX-2 inhibition. PLoS ONE 5:e13713CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lin TH, Chang SJ, Chen CC, Wang JP, Tsao LT (2001) Two phenanthraquinones from Dendrobium moniliforme. J Nat Prod 64:1084–1086CrossRefPubMedGoogle Scholar
  15. 15.
    Unahabhokha T, Chanvorachote P, Pongrakhananon V (2016) The attenuation of epithelial to mesenchymal transition and induction of anoikis by gigantol in human lung cancer H460 cells. Tumour Biol 37:8633–8641CrossRefPubMedGoogle Scholar
  16. 16.
    Charoenrungruang S, Chanvorachote P, Sritularak B, Pongrakhananon V (2014) Gigantol, a bibenzyl from Dendrobium draconis, inhibits the migratory behavior of non-small cell lung cancer cells. J Nat Prod 77:1359–1366CrossRefPubMedGoogle Scholar
  17. 17.
    Busaranon K, Plaimee P, Sritularak B, Chanvorachote P (2016) Moscatilin inhibits epithelial-to-mesenchymal transition and sensitizes anoikis in human lung cancer H460 cells. J Nat Med 70:18–27CrossRefPubMedGoogle Scholar
  18. 18.
    Toyooka T, Shinmen T, Aarts JM, Ibuki Y (2012) Dual effects of N-acetyl-l-cysteine dependent on NQO1 activity: suppressive or promotive of 9, 10-phenanthrenequinone-induced toxicity. Toxicol Appl Pharmacol 264:404–412CrossRefPubMedGoogle Scholar
  19. 19.
    Matsunaga T, Kamiya T, Sumi D, Kumagai Y, Kalyanaraman B, Hara A (2008) l-Xylulose reductase is involved in 9, 10-phenanthrenequinone-induced apoptosis in human T lymphoma cells. Free Radic Biol Med 44:1191–1202CrossRefPubMedGoogle Scholar
  20. 20.
    Matsunaga T, Arakaki M, Kamiya T, Endo S, El-Kabbani O, Hara A (2009) Involvement of an aldo-keto reductase (AKR1C3) in redox cycling of 9, 10-phenanthrenequinone leading to apoptosis in human endothelial cells. Chem Biol Interact 181:52–60CrossRefPubMedGoogle Scholar
  21. 21.
    Saibu M, Sagar S, Green I, Ameer F, Meyer M (2014) Evaluating the cytotoxic effects of novel quinone compounds. Anticancer Res 34:4077–4086PubMedGoogle Scholar
  22. 22.
    Foucquier J, Guedj M (2015) Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect 3:e00149CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Srinual S, Chanvorachote P, Pongrakhananon V (2017) Suppression of cancer stem-like phenotypes in NCI-H460 lung cancer cells by vanillin through an Akt-dependent pathway. Int J Oncol 50:1341–1351CrossRefPubMedGoogle Scholar
  24. 24.
    Reed JC (2000) Mechanisms of apoptosis. Am J Pathol 157:1415–1430CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Wong RS (2011) Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 30:87CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    O’Brien MA, Kirby R (2008) Apoptosis: a review of pro-apoptotic and anti-apoptotic pathways and dysregulation in disease. J Vet Emerg Crit Care 18:572–585CrossRefGoogle Scholar
  27. 27.
    Fischer U, Schulze-Osthoff K (2005) New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev 57:187–215CrossRefPubMedGoogle Scholar
  28. 28.
    Porter AG, Jänicke RU (1999) Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6(2):99–104CrossRefPubMedGoogle Scholar
  29. 29.
    Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378CrossRefPubMedGoogle Scholar
  30. 30.
    Henkels KM, Turchi JJ (1999) Cisplatin-induced apoptosis proceeds by caspase-3-dependent and-independent pathways in cisplatin-resistant and-sensitive human ovarian cancer cell lines. Cancer Res 59:3077–3083PubMedGoogle Scholar
  31. 31.
    Brozovic A, Ambriovic-Ristov A, Osmak M (2010) The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit Rev Toxicol 40:347–359CrossRefPubMedGoogle Scholar
  32. 32.
    Saad SY, Najjar TA, Alashari M (2004) Role of non-selective adenosine receptor blockade and phosphodiesterase inhibition in cisplatin-induced nephrogonadal toxicity in rats. Clin Exp Pharmacol Physiol 31:862–867CrossRefPubMedGoogle Scholar
  33. 33.
    Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB (2012) Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 16:1295–1322CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Fuertes MA, Alonso C, Pérez JM (2003) Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 103:645–662CrossRefPubMedGoogle Scholar
  35. 35.
    Sirichanchuen B, Pengsuparp T, Chanvorachote P (2012) Long-term cisplatin exposure impairs autophagy and causes cisplatin resistance in human lung cancer cells. Mol Cell Biochem 364:11–18CrossRefPubMedGoogle Scholar
  36. 36.
    Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994–1007CrossRefPubMedGoogle Scholar
  37. 37.
    Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF, Hamilton TC (1994) Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 47:689–697CrossRefPubMedGoogle Scholar
  38. 38.
    Matsumoto M, Nakajima W, Seike M, Gemma A, Tanaka N (2016) Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells. Biochem Biophys Res Commun 473:490–496CrossRefPubMedGoogle Scholar
  39. 39.
    Unahabhokha T, Chanvorachote P, Sritularak B, Kitsongsermthon J, Pongrakhananon V (2016) Gigantol inhibits epithelial to mesenchymal process in human lung cancer cells. Evid Based Complement Alternat Med 2016:4561674CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Charoenrungruang S, Chanvorachote P, Sritularak B, Pongrakhananon V (2014) Gigantol-induced apoptosis in lung cancer cells through mitochondrial-dependent pathway. Thai J Pharm Sci 38:67–73Google Scholar

Copyright information

© The Japanese Society of Pharmacognosy and Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  • Onsurang Wattanathamsan
    • 1
    • 2
  • Surassawadee Treesuwan
    • 2
    • 3
  • Boonchu Sritularuk
    • 4
  • Varisa Pongrakhananon
    • 2
    • 3
  1. 1.Inter-department Program of Pharmacology, Graduate SchoolChulalongkorn UniversityBangkokThailand
  2. 2.Cell-Based Drug and Health Product Development Research UnitChulalongkorn UniversityBangkokThailand
  3. 3.Department of Pharmacology and Physiology, Faculty of Pharmaceutical SciencesChulalongkorn UniversityBangkokThailand
  4. 4.Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical SciencesChulalongkorn UniversityBangkokThailand

Personalised recommendations